溢多利(300381.SZ):擬1951.36萬元收購鴻鷹生物剩餘9.7568%股權
格隆匯7月28日丨溢多利(300381.SZ)公佈,為進一步完善公司戰略佈局,提高工業酶產品市場競爭力,公司擬以自有資金收購李洪兵所持有的湖南鴻鷹生物科技有限公司(“鴻鷹生物”)9.7568%股權。交易雙方於2021年7月28日簽署了《關於收購湖南鴻鷹生物科技有限公司9.7568%股權之股權轉讓協議》。
經雙方協商,目標公司整體作價2億元,本次收購9.7568%股權對應的交易總價為人民幣1951.36萬元。交易完成後,鴻鷹生物將成為公司的全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.